Johnson & Johnson Showcases Transformation from Expo Exhibitor to Investor at the 5th CIIE with Nearly 200 Innovative Health Solutions

In Sync with the CIIE, Johnson & Johnson Builds a Strong Magnet for a Healthy China

ShanghaiOctober 26, 2022PR Newswire -- At the 5th China International Import Expo (CIIE), Johnson & Johnson, a global leader in healthcare, will once again present nearly 200 innovative products, including about 40 "first-time showcases." As a long-time participant of the CIIE for five consecutive sessions, Johnson & Johnson is leveraging the "acceleration" provided by the CIIE to promote the rapid implementation of innovative medical products and solutions and the widespread availability of quality healthcare resources. Fourteen successful cases will be showcased in the newly established "Exhibitors Become Investors" section at Hall 6.2 during this year’s CIIE. These cases cover three key areas: the implementation of innovation achievements, increased local investment in China, and the co-construction of an innovative ecosystem.

Benefiting the people, innovative medical achievements are being implemented at a faster pace 

Since the first China International Import Expo (CIIE), Johnson & Johnson has benefited from the strong "CIIE magnetism," transforming innovative products and technologies across diverse business areas such as medical technology, pharmaceuticals, and consumer health into medical resources that benefit the general public. This has accelerated the process of medical innovation serving Chinese patients.

Just one month after Johnson & Johnson Medical Technologies' CARTO 3 3D electrophysiology navigation system debuted at the first China International Import Expo (CIIE), it was introduced to China for the first time through a green channel, supported by the "Nine National Policies" of the Boao Lecheng Medical Tourism Pilot Zone in Hainan. This brought Chinese cardiovascular patients cutting-edge heart surgery treatments aligned with international standards. The all-new CARTO 3 3D Electrophysiology Navigation System V7 has also been launched this year, offering personalized treatment strategies combined with flexible and diverse technologies and products. Also on display was the ATTUNE Total Knee System, which was designed with consideration for the skeletal morphology differences of knee patients from various countries and tailored to the skeletal characteristics of Chinese patients. This innovative breakthrough product has successfully entered over 1,200 hospitals in China and benefited more than 50,000 Chinese patients suffering from knee ailments. Focusing on precision, intricacy, and safety, Johnson & Johnson Vision’s "Catalys White Force" ophthalmic femtosecond laser treatment machine was showcased at the third CIIE and received registration approval from the National Medical Products Administration just two months later, enhancing the level of cataract treatment in China. Additionally, ACUVUE OASYS DAILIES Toric, China's first daily disposable silicone hydrogel toric contact lenses, and Stratafix Spiral Plus Antibacterial Knotless Absorbable Sutures made their debut at last year's CIIE, gaining widespread recognition from industry experts and continuous praise from consumers.

"Catalys White Force" Ophthalmic Femtosecond Laser Treatment Machine Officially Receives Registration Approval from the National Medical Products Administration Only Two Months After Its Debut at the Third CIIE

Since participating in the CIIE, several innovative drugs from Janssen, a pharmaceutical subsidiary of Johnson & Johnson, have been rapidly introduced to the Chinese market, bringing innovative treatment solutions to more patients at "China speed." For example, Tremfya, showcased in 2019, is used for adult patients with moderate to severe plaque psoriasis suitable for systemic therapy.^®Approved by the National Medical Products Administration, this is also the world's and China's first approved Interleukin-23 (IL-23) inhibitor; at the same time, DARZALEX exhibited successively at CIIE.^®(Daratumumab Injection), Erleada^®(Apalutamide Tablets) and Stelara^®(Stelara Injection/Ustekinumab Injection for Intravenous Infusion) was included in the National Medical Insurance Catalog at the end of 2021, significantly improving the affordability of innovative drugs for cancer and immune disease patients.

Multiple innovative drugs from Janssen, a pharmaceutical subsidiary of Johnson & Johnson, have also been rapidly launched in the Chinese market.

Johnson & Johnson's "black tech" in the consumer health field has also become a beneficiary of the CIIE. At the fourth CIIE, the Listerine Revitalizing Mouthwash series, specifically tailored for smokers, stood out with its breakthrough NeuAct technology.^TM Smoke Neutralization Technology and Innovative Zinc Chloride Formula Made "Global Debut" at CIIE, Triggering Enthusiastic Market Response, Successfully Launched Across All Channels Online and Offline in China in February 2022. The Upgraded Version of Rhinocort Budesonide Nasal Spray Exhibited the Same Year Also Successfully Entered the Chinese Market This Year; the Improved Nasal Spray Drug Delivery Device Optimized Medication Experience for Patients Long Plagued by Rhinitis, Enhancing Their Quality of Daily Life.

Actively Layout, Increase Investment in Local Production and Manufacturing

Johnson & Johnson also leveraged the unique platform effect of the CIIE to enhance its localization efforts, transforming from an exhibitor into an investor. During the second CIIE, Johnson & Johnson reached a strategic cooperation with the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, aiming to integrate both parties' advantageous resources to promote medical technology, equipment, and pharmaceuticals to align with international advanced standards. As early as 2018, Johnson & Johnson successfully completed the first fully visualized magnetic and electrical dual-positioning cardiac surgery in China at the Boao Super Hospital. After signing the letter of intent for strategic cooperation, Johnson & Johnson Vision’s Catalys conducted the first femtosecond laser cataract surgery in mainland China, and MENTOR under Johnson & Johnson Medical Technologies...^®Xtra Premium Breast Implants Successfully Complete First Surgery in Boao, China, Creating Multiple Medical Milestone Cases in the Industry. Notably, after the second China International Import Expo (CIIE), the "Johnson & Johnson Boao Innovation Chain" was officially launched. On its first anniversary, three major innovative projects were implemented: the launch of the new "Boao·Surgery" brand, the establishment of the "Intelligent Orthopedics R&D and Training Center," and the initiation of the "Comprehensive Atrial Fibrillation Solution Professional Education and Training" program. As an innovative integrated platform for showcasing medical research achievements, promoting technology, applying products, facilitating academic exchange, and training high-end talents, the "Johnson & Johnson Boao Innovation Chain" has become a crucial bridge connecting medical needs in China with advanced global medical technologies and products, highlighting Johnson & Johnson's firm commitment to supporting local innovation.

In addition, the new generation of antimicrobial VICRYL absorbable surgical sutures from Johnson & Johnson Medical Technologies (VICRYL^® Plus) is also one of the typical cases where Johnson & Johnson utilized the China International Import Expo (CIIE) to transform exhibits into commercial products and transition from an exhibitor to an investor. Vicryl with triclosan coating, an antibacterial suture that helps inhibit bacterial colonization on surgical sutures and reduce the risk of surgical site infections, was previously introduced at the CIIE as an imported product. Thanks to the spillover effects, this groundbreaking surgical product successfully rolled off the production line and was delivered from Johnson & Johnson's Suzhou Industrial Park in January this year, becoming a domestically produced item in China.The first surgical suture with triclosan antimicrobial coating produced locally in China fills a domestic gap., which also supports the high-quality development of China's surgical industry, allowing a wide range of doctors and patients to more conveniently enjoy high-quality medical products made in China.

The new generation of antibacterial VICRYL® Plus absorbable sutures successfully rolled off the production line at Johnson & Johnson's Suzhou Industrial Park in January 2022, becoming the first surgical suture containing triclosan antibacterial coating produced in China.

Shared Creation, Innovation Ecosystem Thriving

Innovation has been the core competitiveness of Johnson & Johnson for over 130 years in improving human health and promoting the upgrading and development of the healthcare industry. Riding on the momentum of the CIIE, Johnson & Johnson continues to cultivate fertile ground for innovation, actively collaborating with all parties to build an open innovation ecosystem, accelerating the convergence of innovative resources, and bringing quality medical services to benefit more patients in China.

In 2021, Johnson & Johnson invited seven startups from its JLABS @ Shanghai incubator to appear at the inaugural "Innovation Incubation Zone" of the China International Import Expo (CIIE), showcasing multiple forward-looking medical technology achievements and the latest research advancements. In 2022, JLABS @ Shanghai will once again bring three innovative companies to the Innovation Incubation Zone of the fifth CIIE, further facilitating resource integration, accelerating innovation implementation, and contributing groundbreaking healthcare solutions to patients and consumers.

Song Weiqun, Global Senior Vice President of Johnson & Johnson and Chairman of Johnson & Johnson China, stated: "The CIIE is an important platform for showcasing openness, integration, innovation, and win-win cooperation. As a pioneer with long-term dedication to China's healthcare industry, Johnson & Johnson has been a participant in every edition of the CIIE and has benefited from open collaboration that encourages sharing and co-creation. We look forward to continuing to partner with like-minded collaborators on the CIIE platform to achieve more innovative breakthroughs in healthcare that benefit the general public, and together advance towards a 'shared, co-created, and win-win' healthy future."